The Latest Breaking News from Zimmer BioMet

Zimmer Biomet has underperformed the healthcare sector over the past year, yet analysts remain moderately bullish about the stock’s prospects.

Zimmer Biomet stock tumbled Thursday after the medtech company said implementing a new enterprise system would slug 2024 sales by 1%.

The announcement has left a community in shock

Zimmer Biomet has confirmed plans to close its factory in Bridgend

Zimmer Biomet in Bridgend has entered into consultation with its staff

The market rally held up, for now, amid a Fed forecast of two more rate hikes. Tesla ended a big win streak. Medical product firms flashed buy signals.

Masimo Corporation (NASDAQ: MASI) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%.

SVB Leerink has decided to maintain its Outperform rating of Zimmer Biomet Holdings (NYSE:ZBH) and raise its price target from $135.00 to $140.00. Shares of Zimmer Biomet Holdings are trading up 0.82% over the last 24 hours, at $121.67 per share.

Zimmer Biomet Holdings Inc's (NYSE:ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis), beating the consensus of $1.59 billion. Adjusted EPS was $1.61, which came in above the consensus of $1.41 and $1.55 a year ago. "We are encouraged by the better than expected results…